A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Encouse Golden, M.D., Ph.D.
Weill Medical College of Cornell University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Brooklyn Methodist Hospital - Newyork Presbyterian
New York, New York, United States
Hani Ashamalla, M.D.Recruiting - New York Presbyterian Hospital - Queens
New York, New York, United States
Andrew Brandmaier, M.D.Recruiting - Weill Cornell Medical College
New York, New York, United States
Encouse Golden, M.D., Ph.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2022
- Primary completion
- 31 Dec 2026
- Completion
- 31 Dec 2030
- Last update posted
- 27 Aug 2025
- Registered enrollment
- 43
- Registry id
- NCT05024097
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.